NASDAQ:HUGE

FSD Pharma Competitors

$1.56
-0.03 (-1.89 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.52
Now: $1.56
$1.62
50-Day Range
$1.59
MA: $1.96
$2.39
52-Week Range
$1.28
Now: $1.56
$14.00
Volume708,662 shs
Average Volume3.66 million shs
Market Capitalization$29.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.39

Competitors

FSD Pharma (NASDAQ:HUGE) Vs. CGC, APHA, CRON, TLRY, USNA, and ACB

Should you be buying HUGE stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to FSD Pharma, including Canopy Growth (CGC), Aphria (APHA), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), and Aurora Cannabis (ACB).

Canopy Growth (NASDAQ:CGC) and FSD Pharma (NASDAQ:HUGE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Volatility & Risk

Canopy Growth has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Earnings & Valuation

This table compares Canopy Growth and FSD Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million35.73$-993,370,000.00$1.3221.06
FSD Pharma$190,000.00157.33$-39,200,000.00($5.55)-0.28

FSD Pharma has lower revenue, but higher earnings than Canopy Growth. FSD Pharma is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.2% of Canopy Growth shares are held by institutional investors. Comparatively, 0.7% of FSD Pharma shares are held by institutional investors. 0.3% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Canopy Growth and FSD Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
FSD PharmaN/A-111.76%-92.92%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Canopy Growth and FSD Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth510211.94
FSD Pharma00103.00

Canopy Growth currently has a consensus price target of $35.6778, indicating a potential upside of 28.34%. Given FSD Pharma's stronger consensus rating and higher probable upside, analysts clearly believe FSD Pharma is more favorable than Canopy Growth.

Summary

Canopy Growth beats FSD Pharma on 9 of the 15 factors compared between the two stocks.

FSD Pharma (NASDAQ:HUGE) and Aphria (NASDAQ:APHA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Institutional and Insider Ownership

0.7% of FSD Pharma shares are owned by institutional investors. Comparatively, 10.3% of Aphria shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

FSD Pharma has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, indicating that its stock price is 167% more volatile than the S&P 500.

Profitability

This table compares FSD Pharma and Aphria's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FSD PharmaN/A-111.76%-92.92%
Aphria-36.10%-2.30%-1.66%

Analyst Ratings

This is a summary of recent ratings for FSD Pharma and Aphria, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FSD Pharma00103.00
Aphria05302.38

Aphria has a consensus target price of $22.00, indicating a potential upside of 55.59%. Given FSD Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe FSD Pharma is more favorable than Aphria.

Earnings & Valuation

This table compares FSD Pharma and Aphria's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FSD Pharma$190,000.00157.33$-39,200,000.00($5.55)-0.28
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67

FSD Pharma has higher earnings, but lower revenue than Aphria. Aphria is trading at a lower price-to-earnings ratio than FSD Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Aphria beats FSD Pharma on 7 of the 13 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and FSD Pharma (NASDAQ:HUGE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cronos Group and FSD Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group24101.86
FSD Pharma00103.00

Cronos Group presently has a consensus price target of $8.75, indicating a potential upside of 4.67%. Given FSD Pharma's stronger consensus rating and higher probable upside, analysts clearly believe FSD Pharma is more favorable than Cronos Group.

Earnings & Valuation

This table compares Cronos Group and FSD Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million117.46$1.17 billion$0.6712.48
FSD Pharma$190,000.00157.33$-39,200,000.00($5.55)-0.28

Cronos Group has higher revenue and earnings than FSD Pharma. FSD Pharma is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cronos Group has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Institutional & Insider Ownership

11.8% of Cronos Group shares are held by institutional investors. Comparatively, 0.7% of FSD Pharma shares are held by institutional investors. 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Cronos Group and FSD Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
FSD PharmaN/A-111.76%-92.92%

Summary

Cronos Group beats FSD Pharma on 10 of the 13 factors compared between the two stocks.

Tilray (NASDAQ:TLRY) and FSD Pharma (NASDAQ:HUGE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Volatility & Risk

Tilray has a beta of 3.12, meaning that its stock price is 212% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Institutional and Insider Ownership

12.6% of Tilray shares are owned by institutional investors. Comparatively, 0.7% of FSD Pharma shares are owned by institutional investors. 16.8% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Tilray and FSD Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tilray19001.90
FSD Pharma00103.00

Tilray presently has a consensus target price of $18.3078, indicating a potential upside of 6.44%. Given FSD Pharma's stronger consensus rating and higher possible upside, analysts plainly believe FSD Pharma is more favorable than Tilray.

Profitability

This table compares Tilray and FSD Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tilray-242.60%-92.70%-20.70%
FSD PharmaN/A-111.76%-92.92%

Valuation and Earnings

This table compares Tilray and FSD Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray$166.98 million17.69$-321,170,000.00($1.69)-10.18
FSD Pharma$190,000.00157.33$-39,200,000.00($5.55)-0.28

FSD Pharma has lower revenue, but higher earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than FSD Pharma, indicating that it is currently the more affordable of the two stocks.

FSD Pharma (NASDAQ:HUGE) and USANA Health Sciences (NYSE:USNA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares FSD Pharma and USANA Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FSD PharmaN/A-111.76%-92.92%
USANA Health Sciences10.57%32.91%22.26%

Risk & Volatility

FSD Pharma has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Institutional & Insider Ownership

0.7% of FSD Pharma shares are owned by institutional investors. Comparatively, 54.1% of USANA Health Sciences shares are owned by institutional investors. 45.4% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares FSD Pharma and USANA Health Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FSD Pharma$190,000.00157.33$-39,200,000.00($5.55)-0.28
USANA Health Sciences$1.06 billion1.92$100.53 million$4.4122.42

USANA Health Sciences has higher revenue and earnings than FSD Pharma. FSD Pharma is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for FSD Pharma and USANA Health Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FSD Pharma00103.00
USANA Health Sciences00203.00

USANA Health Sciences has a consensus target price of $126.00, suggesting a potential upside of 27.41%. Given FSD Pharma's higher probable upside, research analysts clearly believe FSD Pharma is more favorable than USANA Health Sciences.

Summary

USANA Health Sciences beats FSD Pharma on 10 of the 13 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and FSD Pharma (NASDAQ:HUGE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Aurora Cannabis and FSD Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis69001.60
FSD Pharma00103.00

Aurora Cannabis currently has a consensus price target of $10.9264, suggesting a potential upside of 38.66%. Given FSD Pharma's stronger consensus rating and higher probable upside, analysts clearly believe FSD Pharma is more favorable than Aurora Cannabis.

Earnings and Valuation

This table compares Aurora Cannabis and FSD Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million7.50$-2,468,190,000.00($2.86)-2.76
FSD Pharma$190,000.00157.33$-39,200,000.00($5.55)-0.28

FSD Pharma has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than FSD Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aurora Cannabis and FSD Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
FSD PharmaN/A-111.76%-92.92%

Risk & Volatility

Aurora Cannabis has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Institutional & Insider Ownership

11.9% of Aurora Cannabis shares are held by institutional investors. Comparatively, 0.7% of FSD Pharma shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Aurora Cannabis beats FSD Pharma on 7 of the 13 factors compared between the two stocks.


FSD Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Canopy Growth logo
CGC
Canopy Growth
1.0$27.80-1.4%$10.62 billion$297.34 million-8.32News Coverage
Aphria logo
APHA
Aphria
1.6$14.14-3.9%$4.48 billion$405.96 million-23.97Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
Cronos Group logo
CRON
Cronos Group
0.8$8.36-2.6%$3.01 billion$25.64 million34.83Analyst Downgrade
Tilray logo
TLRY
Tilray
1.0$17.20-1.5%$2.95 billion$166.98 million-3.79News Coverage
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$98.89-2.6%$2.04 billion$1.06 billion18.31Analyst Downgrade
Aurora Cannabis logo
ACB
Aurora Cannabis
1.5$7.88-1.1%$1.56 billion$207.89 million-0.32Analyst Downgrade
Sundial Growers logo
SNDL
Sundial Growers
1.0$0.85-1.2%$1.41 billion$75.86 million-0.33Analyst Upgrade
Gap Up
HEXO logo
HEXO
HEXO
1.1$5.52-3.3%$676.12 million$60.46 million-1.13Gap Up
ChromaDex logo
CDXC
ChromaDex
1.3$8.20-4.0%$547.41 million$46.29 million-21.58
MediWound logo
MDWD
MediWound
1.4$5.04-2.0%$137.27 million$31.79 million-12.60Decrease in Short Interest
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$18.20-6.3%$115.72 million$118.88 million227.53High Trading Volume
Increase in Short Interest
Gap Up
HAPP
Happiness Biotech Group
0.6$1.84-0.5%$47.53 million$65.06 million0.00Increase in Short Interest
News Coverage
Mannatech logo
MTEX
Mannatech
1.3$19.13-2.4%$39.58 million$157.73 million5.89Gap Down
CYAN
Cyanotech
0.6$3.14-1.6%$19.15 million$31.90 million31.40
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.